Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a tafasitamab study in adults with primary ITP or primary warm autoimmune hemolytic anemia
NL-OMON60598Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of tafasitamab in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) (2 cohorts), sponsored by Incyte. Primary endpoints: Safety and tolerability, Stable platelet response and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON60598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60598.